Pharmacogenomics and Personalized Medicine

Pharmacogenomics is one of the emerging approaches to precision medicine, tailoring drug selection and dosing to the patient’s genetic features. In recent years, several pharmacogenetic guidelines have been published by international scientific consortia, but the uptake in clinical practice is still...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Format: Online
Jezik:angleščina
Izdano: MDPI - Multidisciplinary Digital Publishing Institute 2021
Teme:
Online dostop:ONIX_20210501_9783039367306_679
Oznake: Označite
Brez oznak, prvi označite!
_version_ 1869517875767672832
collection Directory of Open Access Books
description Pharmacogenomics is one of the emerging approaches to precision medicine, tailoring drug selection and dosing to the patient’s genetic features. In recent years, several pharmacogenetic guidelines have been published by international scientific consortia, but the uptake in clinical practice is still poor. Many coordinated international efforts are ongoing in order to overcome the existing barriers to pharmacogenomic implementation. On the other hand, existing validated pharmacogenomic markers can explain only a minor part of the observed clinical variability in the therapeutic outcome. New investigational approaches are warranted, including a study of the pharmacogenomic role of the immune system genetics and of previously neglected rare genetic variants, reported to account for a large part of inter-individual variability in drug metabolism. In this book, we have collected a series of articles covering many aspects of pharmacogenomics. These include clinical implementation of pharmacogenomics in clinical practice, development of tools or infrastructures to support this process, research of new pharmacogenomics markers to increase drug efficacy and safety, and the impact of rare genetic variants in pharmacogenomics.
format Online
id doab-20.500.12854ir-68933
institution Directory of Open Access Books
language eng
publishDate 2021
publishDateRange 2021
publishDateSort 2021
publisher MDPI - Multidisciplinary Digital Publishing Institute
publisherStr MDPI - Multidisciplinary Digital Publishing Institute
record_format ojs
spelling doab-20.500.12854ir-689332024-03-30T23:22:12Z Pharmacogenomics and Personalized Medicine Cecchin, Erika Stocco, Gabriele CYP2C9 VKORC1 warfarin warfarin initiation phase of therapy INR pharmacogenetics study pharmacogenomics pharmacogenetics genotype phenotype alleles precision medicine pharmacotranscriptomics high-throughput analysis childhood acute lymphoblastic leukemia clopidogrel acenocoumarol CDSS implementation azathioprine inflammatory bowel disease glutathione-S transferase pharmacokinetics nucleoside analogs microRNAs gene expression drug resistance AML cisplatin nephrotoxicity kidney injury genetic polymorphisms pre-emptive panel breast cancer subtype miRNA pathway crosstalk network precision drugs ovarian cancer platinum resistance focal copy number alterations whole exome sequencing personalized medicine human genetics pharmacology thema EDItEUR::M Medicine and Nursing Pharmacogenomics is one of the emerging approaches to precision medicine, tailoring drug selection and dosing to the patient’s genetic features. In recent years, several pharmacogenetic guidelines have been published by international scientific consortia, but the uptake in clinical practice is still poor. Many coordinated international efforts are ongoing in order to overcome the existing barriers to pharmacogenomic implementation. On the other hand, existing validated pharmacogenomic markers can explain only a minor part of the observed clinical variability in the therapeutic outcome. New investigational approaches are warranted, including a study of the pharmacogenomic role of the immune system genetics and of previously neglected rare genetic variants, reported to account for a large part of inter-individual variability in drug metabolism. In this book, we have collected a series of articles covering many aspects of pharmacogenomics. These include clinical implementation of pharmacogenomics in clinical practice, development of tools or infrastructures to support this process, research of new pharmacogenomics markers to increase drug efficacy and safety, and the impact of rare genetic variants in pharmacogenomics. 2021-05-01T15:33:04Z 2021-05-01T15:33:04Z 2020 book ONIX_20210501_9783039367306_679 9783039367306 9783039367313 https://directory.doabooks.org/handle/20.500.12854/68933 eng application/octet-stream Attribution 4.0 International https://mdpi.com/books/pdfview/book/2700 https://mdpi.com/books/pdfview/book/2700 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-03936-731-3 10.3390/books978-3-03936-731-3 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783039367306 9783039367313 208 Basel, Switzerland open access
spellingShingle CYP2C9
VKORC1
warfarin
warfarin initiation phase of therapy
INR
pharmacogenetics study
pharmacogenomics
pharmacogenetics
genotype
phenotype
alleles
precision medicine
pharmacotranscriptomics
high-throughput analysis
childhood acute lymphoblastic leukemia
clopidogrel
acenocoumarol
CDSS
implementation
azathioprine
inflammatory bowel disease
glutathione-S transferase
pharmacokinetics
nucleoside analogs
microRNAs
gene expression
drug resistance
AML
cisplatin
nephrotoxicity
kidney injury
genetic polymorphisms
pre-emptive
panel
breast cancer subtype
miRNA
pathway
crosstalk network
precision drugs
ovarian cancer
platinum resistance
focal copy number alterations
whole exome sequencing
personalized medicine
human genetics
pharmacology
thema EDItEUR::M Medicine and Nursing
Pharmacogenomics and Personalized Medicine
title Pharmacogenomics and Personalized Medicine
title_full Pharmacogenomics and Personalized Medicine
title_fullStr Pharmacogenomics and Personalized Medicine
title_full_unstemmed Pharmacogenomics and Personalized Medicine
title_short Pharmacogenomics and Personalized Medicine
title_sort pharmacogenomics and personalized medicine
topic CYP2C9
VKORC1
warfarin
warfarin initiation phase of therapy
INR
pharmacogenetics study
pharmacogenomics
pharmacogenetics
genotype
phenotype
alleles
precision medicine
pharmacotranscriptomics
high-throughput analysis
childhood acute lymphoblastic leukemia
clopidogrel
acenocoumarol
CDSS
implementation
azathioprine
inflammatory bowel disease
glutathione-S transferase
pharmacokinetics
nucleoside analogs
microRNAs
gene expression
drug resistance
AML
cisplatin
nephrotoxicity
kidney injury
genetic polymorphisms
pre-emptive
panel
breast cancer subtype
miRNA
pathway
crosstalk network
precision drugs
ovarian cancer
platinum resistance
focal copy number alterations
whole exome sequencing
personalized medicine
human genetics
pharmacology
thema EDItEUR::M Medicine and Nursing
topic_facet CYP2C9
VKORC1
warfarin
warfarin initiation phase of therapy
INR
pharmacogenetics study
pharmacogenomics
pharmacogenetics
genotype
phenotype
alleles
precision medicine
pharmacotranscriptomics
high-throughput analysis
childhood acute lymphoblastic leukemia
clopidogrel
acenocoumarol
CDSS
implementation
azathioprine
inflammatory bowel disease
glutathione-S transferase
pharmacokinetics
nucleoside analogs
microRNAs
gene expression
drug resistance
AML
cisplatin
nephrotoxicity
kidney injury
genetic polymorphisms
pre-emptive
panel
breast cancer subtype
miRNA
pathway
crosstalk network
precision drugs
ovarian cancer
platinum resistance
focal copy number alterations
whole exome sequencing
personalized medicine
human genetics
pharmacology
thema EDItEUR::M Medicine and Nursing
url ONIX_20210501_9783039367306_679